OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors
OptimizeRx (NASDAQ: OPRX), a healthcare technology solutions provider, has appointed CEO Steve Silvestro to its Board of Directors, effective June 20, 2025. Silvestro, who joined the company in 2019, has served as CEO since March 2025, following his interim CEO role from January 2025.
Under Silvestro's leadership, the company has made significant progress in strengthening its market position. His strategic focus includes enhancing customer experiences, deepening pharmaceutical partnerships, transitioning to a recurring revenue model, and advancing toward Rule of 40 performance. Board Chairperson Lynn Vos expressed confidence in Silvestro's leadership and the company's foundation for long-term value creation.
OptimizeRx (NASDAQ: OPRX), fornitore di soluzioni tecnologiche per il settore sanitario, ha nominato il CEO Steve Silvestro nel suo Consiglio di Amministrazione, con effetto dal 20 giugno 2025. Silvestro, entrato in azienda nel 2019, ricopre il ruolo di CEO da marzo 2025, dopo aver svolto la funzione di CEO ad interim da gennaio 2025.
Sotto la guida di Silvestro, l'azienda ha compiuto notevoli progressi nel rafforzare la propria posizione sul mercato. La sua strategia si concentra sul miglioramento dell'esperienza cliente, sull'approfondimento delle partnership con le aziende farmaceutiche, sulla transizione verso un modello di ricavi ricorrenti e sull'avanzamento verso la performance secondo la Regola del 40. La Presidente del Consiglio, Lynn Vos, ha espresso fiducia nella leadership di Silvestro e nelle solide basi dell'azienda per la creazione di valore a lungo termine.
OptimizeRx (NASDAQ: OPRX), proveedor de soluciones tecnológicas para el sector salud, ha nombrado al CEO Steve Silvestro como miembro de su Junta Directiva, con efecto a partir del 20 de junio de 2025. Silvestro, que se unió a la empresa en 2019, ha sido CEO desde marzo de 2025, tras desempeñar el cargo de CEO interino desde enero de 2025.
Bajo el liderazgo de Silvestro, la compañía ha avanzado significativamente en el fortalecimiento de su posición en el mercado. Su enfoque estratégico incluye mejorar la experiencia del cliente, profundizar las alianzas farmacéuticas, la transición hacia un modelo de ingresos recurrentes y avanzar hacia el cumplimiento de la Regla del 40. La presidenta de la Junta, Lynn Vos, expresó confianza en el liderazgo de Silvestro y en la base sólida de la empresa para la creación de valor a largo plazo.
OptimizeRx (NASDAQ: OPRX)는 헬스케어 기술 솔루션 제공업체로서, 2025년 6월 20일부터 CEO Steve Silvestro를 이사회 멤버로 임명했습니다. Silvestro는 2019년에 회사에 합류했으며, 2025년 1월부터 임시 CEO를 맡다가 3월부터 정식 CEO로 재직 중입니다.
Silvestro의 리더십 아래 회사는 시장 내 입지 강화에 큰 진전을 이뤘습니다. 그의 전략적 초점은 고객 경험 향상, 제약사와의 파트너십 심화, 반복 수익 모델로의 전환, 그리고 Rule of 40 성과 달성을 향한 진전입니다. 이사회 의장 Lynn Vos는 Silvestro의 리더십과 회사의 장기적 가치 창출 기반에 대한 신뢰를 표명했습니다.
OptimizeRx (NASDAQ : OPRX), fournisseur de solutions technologiques pour le secteur de la santé, a nommé le PDG Steve Silvestro au sein de son conseil d'administration, à compter du 20 juin 2025. Silvestro, qui a rejoint l'entreprise en 2019, occupe le poste de PDG depuis mars 2025, après avoir assuré la fonction de PDG par intérim depuis janvier 2025.
Sous la direction de Silvestro, l'entreprise a réalisé des progrès significatifs pour renforcer sa position sur le marché. Sa stratégie se concentre sur l'amélioration de l'expérience client, le renforcement des partenariats pharmaceutiques, la transition vers un modèle de revenus récurrents et l'avancement vers la performance selon la règle des 40. La présidente du conseil, Lynn Vos, a exprimé sa confiance dans le leadership de Silvestro et dans les bases solides de l'entreprise pour la création de valeur à long terme.
OptimizeRx (NASDAQ: OPRX), ein Anbieter von Gesundheitstechnologielösungen, hat CEO Steve Silvestro mit Wirkung zum 20. Juni 2025 in den Vorstand berufen. Silvestro, der 2019 zum Unternehmen kam, ist seit März 2025 CEO, nachdem er seit Januar 2025 interimistisch diese Position innehatte.
Unter Silvestros Führung hat das Unternehmen bedeutende Fortschritte bei der Stärkung seiner Marktposition erzielt. Sein strategischer Fokus liegt auf der Verbesserung der Kundenerfahrungen, der Vertiefung pharmazeutischer Partnerschaften, dem Übergang zu einem wiederkehrenden Erlösmodell und der Erreichung der Rule-of-40-Leistung. Vorstandsvorsitzende Lynn Vos zeigte sich zuversichtlich in Silvestros Führung und die solide Grundlage des Unternehmens für langfristige Wertschöpfung.
- CEO Steve Silvestro's appointment to Board strengthens leadership continuity
- Company reports meaningful progress in strengthening market position with customers
- Strategic shift towards recurring revenue model indicates potential for stable future earnings
- Focus on Rule of 40 performance demonstrates commitment to balanced growth and profitability
- None.
WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025.
Mr. Silvestro joined the Company in 2019 and has been the Company’s CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and greatly contribute to the Company’s ability to execute its value creation plans and support key initiatives to deliver on its customer and shareholder roadmap.
“The Board of Directors has been impressed with Steve’s leadership and the meaningful progress the Company has made since he stepped into the CEO role,” said Lynn Vos, Chairperson of OptimizeRx’s Board of Directors. “The initiatives he and the leadership team have executed have significantly strengthened OptimizeRx’s position with customers and laid a solid foundation for sustained long-term shareholder value creation. We’re pleased to welcome Steve to the Board and look forward to his continued contributions as we work together to refine and advance the Company’s strategic direction.”
“It's truly an honor to have the trust of such an experienced Board and be able to lead a team that is focused on operational excellence and customer delight,” added Steve Silvestro. “I am excited with the direction OptimizeRx is headed and believe we're firmly positioned for a strong 2025 and are building a solid foundation for continued growth and execution in 2026 and beyond. I’m excited to join the Company’s Board and look forward to continuing to partner with our team, strategic partners, and customers as we continue to drive the Company’s growth. Our focus will remain on delivering exceptional customer experiences, deepening our value proposition with pharmaceutical partners, accelerating our shift toward a recurring revenue model, and progressing toward Rule of 40 performance.”
About Stephen L. Silvestro
Steve Silvestro was appointed Chief Executive Officer in March 2025. He joined the Company as Chief Commercial Officer in April 2019 and has since served as President from October 2023 until his appointment as interim CEO in January 2025. Prior to joining the Company, Mr. Silvestro was with CCH® Tagetik, a Wolters Kluwer company that provides corporate performance management software solutions for planning, consolidation and reporting, as its Vice President and General Manager from January 2018 until April 2019. From April 2017 to January 2018, Mr. Silvestro was with Prognos Health, Inc., a healthcare data and analytics company, as its Chief Commercial Officer and, before that, from September 2007 to April 2017, he was with Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, in various capacities with him last serving as Executive Vice President, Head of Global Sales.
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates", "believes", "estimates", "expects", "forecasts", "intends", "plans", "projects", "targets", "designed", "could", "may", "should", "will" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to OptimizeRx’s commitment to appointing directors who have perspectives, insights, experiences, and skills that expand the depth and breadth of the Board, executing the Company’s value creation plans, supporting key initiatives, advancing the Company’s strategic direction, delivering exceptional customer experiences, deepening the Company’s value proposition with pharmaceutical partners, accelerating the Company’s shift towards a recurring revenue model, progressing towards a Rule of 40 performance, and other statements relating to future performance, plans, and expectations. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to identify and appoint a new independent director, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Investor Relations Contact
Steven Halper
LifeSci Advisors, LLC
shalper@lifesciadvisors.com
FAQ
When did Steve Silvestro become CEO of OptimizeRx (OPRX)?
What are OptimizeRx's (OPRX) strategic priorities under CEO Steve Silvestro?
When did Steve Silvestro join OptimizeRx's Board of Directors?
How long has Steve Silvestro been with OptimizeRx (OPRX)?
Who is the Chairperson of OptimizeRx's Board of Directors?
